Details of 113 children included in this study with kidney disease on immunosuppressive medication
| Median age (IQR) | 13 years (7–16 years) |
| Gender | 51% female, 49% male |
| Underlying kidney disease and reason for immunosuppression (%) | 53 kidney transplantation (47%) 30 nephrotic syndrome (27%) 11 SLE (10%) 7 other glomerulonephritis/vasculitis (6%) 2 ANCA associated vasculitis (2%) 2 IgA Nephropathy (2%) 2 IgAVN-HSPN (2%) 2 atypical HUS (2%) 1 C3GN (1%) 1 tubulointersitial nephritis (1%) 1 ESKD with IBD (1%) 1 tuberous sclerosis (1%) |
| Children on dialysis (%) | 9 haemodialysis (8%)—four kidney transplant, 1 nephrotic syndrome, 4 glomerulonephritis/ANCA 3 peritoneal dialysis (3%)—1 transplant, 1 nephrotic syndrome, 1 IgAN |
| Coexistent pulmonary disease (%) | 4 bacterial/fungal pneumonia (4%) 2 asthma/bronchospasm (2%) |
| Coexistent cardiac disease (%) | 4 left ventricular dysfunction/hypertrophy (4%) |
| Number of children on each type of immunosuppression (%) | 86 on glucocorticoids (76%) 58 on tacrolimus (51%) 61 on mycophenolate mofetil (54%) 11 having had rituximab (10%) 9 on azathioprine (8%) 8 on ciclosporine (7%) 8 on cyclophosphamide (7%) 5 on sirolimus (4%) 3 having had basiliximab (3%) 3 on everolimus (3%) 2 having had ATG (2%) 2 on eculizumab (2%) 1 having had ofatumumab (1%) 1 having had alemtuzumab (1%) 1 on adalimumab (1%) 1 on levamisole (1%) |
ANCA, Anti-neutrophil cytoplasmic antibody; ATG, antithymocyte globulin; C3GN, C3 glomerulopathy; ESKD, end-stage kidney disease; HSPN, Henoch-Schönlein purpura nephritis; HUS, haemolytic uraemic syndrome; IBD, inflammatory bowel disease; IgAN, IgA Nephropathy; IgAVN, IgA vasculitis nephritis ; SLE, systemic lupus erythematosus.